Clinical Trial Update: Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing VPM1002 to the BCG vaccine for prevention of tuberculosis infection in infants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• BCG vaccine (Bacillus Calmette-Guérin)
• VPM1002 (recombinant Bacillus Calmette-Guérin vaccine (rBCG))

Snippet

Sponsor: Serum Institute of India Pvt. Ltd. | Conditions: Mycobacterium Tuberculosis Infection | Phase 3 | Status: COMPLETED